FindTrial
Sign In

NEMVALEUKIN ALFA

DRUG4 trials

Sponsors

Mural Oncology Inc., Mural Oncology, Inc

Conditions

Advanced Solid TumorAdvanced cutaneous melanoma and Advanced mucosal melanomaFallopian TubePlatinum-Resistant Epithelial OvarianSquamous Cell Carcinoma of Head and Neckor Primary Peritoneal Cancer

Phase 1

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Active, not recruitingNCT04592653
Mural Oncology, IncAdvanced Solid Tumor
Start: 2020-09-30End: 2024-12-31Target: 78Updated: 2024-06-07

Phase 2

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
CompletedNCT04144517
Mural Oncology, IncSquamous Cell Carcinoma of Head and Neck
Start: 2020-02-05End: 2022-01-07Updated: 2024-10-16
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
CompletedCTIS2024-513229-22-00
Mural Oncology Inc.Advanced cutaneous melanoma and Advanced mucosal melanoma
Start: 2022-04-21End: 2025-04-15Target: 53Updated: 2025-04-29

Phase 3

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
CompletedCTIS2024-513230-38-00
Mural Oncology Inc.Fallopian Tube, or Primary Peritoneal Cancer, Platinum-Resistant Epithelial Ovarian
Start: 2022-12-15End: 2025-05-09Target: 244Updated: 2025-02-18

Related Papers

Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial.
2025-10-01
Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).
Journal of Clinical Oncology2024-06-011 citations
744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3)
Regular and Young Investigator Award Abstracts2023-10-311 citations
724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)
Regular and Young Investigator Award Abstracts2023-10-31
ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology2022-06-01
432 Nemvaleukin alfa, a novel engineered IL-2 cytokine, in combination with the anti-PD-1 antibody pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (ION-01 study)
Regular and Young Investigator Award Abstracts2021-11-015 citations